88 related articles for article (PubMed ID: 9066005)
1. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin.
Brown NJ; Nadeau JH; Vaughan DE
Thromb Haemost; 1997 Mar; 77(3):522-5. PubMed ID: 9066005
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men.
Pretorius M; Luther JM; Murphey LJ; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2435-40. PubMed ID: 16166566
[TBL] [Abstract][Full Text] [Related]
3. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
4. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
Brown NJ; Ryder D; Gainer JV; Morrow JD; Nadeau J
J Pharmacol Exp Ther; 1996 Nov; 279(2):703-12. PubMed ID: 8930174
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
[TBL] [Abstract][Full Text] [Related]
9. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
[TBL] [Abstract][Full Text] [Related]
10. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
[TBL] [Abstract][Full Text] [Related]
11. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
13. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
[TBL] [Abstract][Full Text] [Related]
15. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Fogari R; Derosa G; Lazzari P; Zoppi A; Fogari E; Rinaldi A; Mugellini A
Am J Hypertens; 2004 Sep; 17(9):823-7. PubMed ID: 15363826
[TBL] [Abstract][Full Text] [Related]
16. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
[TBL] [Abstract][Full Text] [Related]
18. Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension.
Korbut RA; Madej J; Adamek-Guzik T; Korbut R
J Physiol Pharmacol; 2003 Sep; 54(3):397-408. PubMed ID: 14566078
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.
Pretorius M; McFarlane JA; Vaughan DE; Brown NJ; Murphey LJ
Clin Pharmacol Ther; 2004 Oct; 76(4):379-87. PubMed ID: 15470338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
